Anixa Biosciences (ANIX) Liabilities and Shareholders Equity (2010 - 2026)

Anixa Biosciences (ANIX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $14.9 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 12.44% year-over-year to $14.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $65.6 million (down 18.42% YoY) and the FY2025 annual result came in at $16.1 million, down 25.52% from the prior year.
• Liabilities and Shareholders Equity eased to $14.9 million in Q2 2026, from $16.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $35.2 million in Q1 2022 to a low of $14.9 million in Q2 2026.
• A 5-year average of $24.6 million and a median of $25.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 141.28% — and 2025, when it plunged 30.29%.
• Tracing ANIX's Liabilities and Shareholders Equity over 5 years: stood at $30.4 million in 2022, then decreased by 16.08% to $25.5 million in 2023, then declined by 15.4% to $21.6 million in 2024, then decreased by 25.52% to $16.1 million in 2025, then slipped by 7.56% to $14.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $14.9 million (Q2 2026), $16.1 million (Q4 2025), and $17.7 million (Q3 2025), per Business Quant data.